Nurix Therapeutics reported a net income of $549.8 million, or $4.73 per diluted share, for the fiscal quarter ended August 31, 2026, compared to a net loss of $86.4 million in the prior-year period. Revenue surged to $673.1 million from $7.9 million, driven primarily by a $653.2 million license payment from Roche and a $10.0 million milestone from Sanofi. The company ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities. Clinically, Nurix dosed the first patient in its Phase 3 DAYBreak CLL-306 trial for bexobrutideg and advanced NX-1607 into Phase 1b expansion cohorts across four solid tumor indications. The company is a clinical-stage biopharmaceutical firm focused on targeted protein degradation medicines.
